Table 3. Relapse-Free Survival (RFS) and Overall Survival (OS) by total cMET and phospho-cMET levels and breast cancer subtype.

				Relapse-Free Survival (RFS)				Overall Survival (OS)
Tumor Subtypes	Protein Level		Patients	Events	5-year RFS (%)	95% CI	P	Events	5-year OS (%)	95% CI	P
Overall	cMET	High	181	63	61.3	53.2-70.7	0.003	43	72.4	64.7-81.0	0.003
		Low	76	13	78.9	68.6-90.8		7	93.3	87.8-99.2
	p-cMET	High	123	45	58.9	49.1-70.7	0.033	32	72.4	63.7-82.3	0.025
		Low	134	31	73.8	65.6-83.1		18	85.8	79.4-92.7
Hormone receptor-positive	cMET	High	103	31	65.4	54.7-78.2	0.014	17	82.8	75.0-91.3	0.006
		Low	37	4	85.3	78.2-100		1	100	NA-NA
	p-cMET	High	75	21	67.6	55.6-82.2	0.519	11	85.2	77.0-94.2	0.519
		Low	65	14	75.1	63.3-89.2		7	90.4	82.6-99.0
HER2-positive	cMET	High	40	17	55.5	40.8-75.4	0.530	13	59.4	41.4-85.2	0.138
		Low	13	4	0.00	NA-NA		1	100	NA-NA
	p-cMET	High	25	15	36.5	19.5-68.3	0.019	12	52.3	33.3-82.2	0.014
		Low	28	6	74.1	57.4-95.5		2	91.7	81.3-100
Triple receptor-negative	cMET	High	38	15	59.5	45.5-77.7	0.086	13	56.1	38.0-82.7	0.187
		Low	26	5	80.4	66.4-97.4		5	66.2	66.2-97.4
	p-cMET	High	23	9	60.9	43.9-84.5	0.251	9	58.8	41.1-84.1	0.128
		Low	41	11	72.3	59.6-87.7		9	74.2	60.5-91.0

CI: Confidence Interval, cMET: Total cMET, p-cMET: Phospho-cMET